255 related articles for article (PubMed ID: 33203201)
1. [Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].
Wang S; Shi Y; Han X
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):1014-1022. PubMed ID: 33203201
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract][Full Text] [Related]
3. Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022.
Huang Y; Zhang L
Cancer Innov; 2023 Feb; 2(1):25-35. PubMed ID: 38090373
[TBL] [Abstract][Full Text] [Related]
4. Impact of non-canonical ALK fusion on the efficacy of targeted therapy in non-small cell lung cancer.
Zeng H; Wei Q; Tang Y; Zhang Y; Tan S; Huang Q; Pu X; Li Y; Tian P
Chin Med J (Engl); 2023 Nov; ():. PubMed ID: 38032041
[No Abstract] [Full Text] [Related]
5. Erratum to: Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC.
Rao W; Liu Y; Li Y; Guo L; Qiu T; Dong L; Ying J; Li W
Front Med; 2024 Apr; ():. PubMed ID: 38700643
[No Abstract] [Full Text] [Related]
6. First-Line Lorlatinib or Crizotinib in Advanced
Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
[TBL] [Abstract][Full Text] [Related]
7. Novel
Latif H; Liu SV
Transl Lung Cancer Res; 2020 Oct; 9(5):2145-2148. PubMed ID: 33209633
[TBL] [Abstract][Full Text] [Related]
8. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.
Kauffmann-Guerrero D; Kahnert K; Huber RM
Drugs; 2021 Jan; 81(1):87-100. PubMed ID: 33226527
[TBL] [Abstract][Full Text] [Related]
9. The effect of metformin in EML
Bland AR; Shrestha N; Bower RL; Rosengren RJ; Ashton JC
Biochem Pharmacol; 2021 Jan; 183():114345. PubMed ID: 33227290
[TBL] [Abstract][Full Text] [Related]
10. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
11. Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M; Yoshida T; Kumagai T; Hida T; Toyozawa R; Shimokawaji T; Goto K; Nakagawa K; Ohe Y; Seto T; Kudou K; Asato T; Zhang P; Yamamoto N
J Thorac Oncol; 2021 Mar; 16(3):452-463. PubMed ID: 33248320
[TBL] [Abstract][Full Text] [Related]
12. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
Wu YL; Shi Y; Tan DSW; Xiaoqing L; Cheng Y; Zhou J; An TT; Lu Y; Zhu B; Bai C; Passos VQ; Lau YY; Xun L; Zhang L
Lung Cancer; 2020 Dec; 150():240-246. PubMed ID: 33249379
[TBL] [Abstract][Full Text] [Related]
13. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
14. Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis-inhibiting pathway.
Yu R; Bai H; Gao B; Li T; He X; Zhang P; Wang J
Thorac Cancer; 2021 Jan; 12(1):128-132. PubMed ID: 33225619
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.
Hohmann N; Bozorgmehr F; Christopoulos P; Mikus G; Blank A; Burhenne J; Thomas M; Haefeli WE
Clin Transl Sci; 2021 Mar; 14(2):487-491. PubMed ID: 33222380
[TBL] [Abstract][Full Text] [Related]
16. Relevance of sun safety in patients commencing crizotinib for non-small cell lung cancer.
Heynemann S; Mitchell P
Australas J Dermatol; 2021 May; 62(2):e332-e333. PubMed ID: 33216964
[No Abstract] [Full Text] [Related]
17. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
18. The Road Less Traveled: A Guide to Metastatic
Almquist D; Ernani V
JCO Oncol Pract; 2021 Jan; 17(1):7-14. PubMed ID: 33211628
[TBL] [Abstract][Full Text] [Related]
19. Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review.
Jiang L; Meng X; Zhao X; Xing L; Yu J
Transl Lung Cancer Res; 2020 Oct; 9(5):2137-2144. PubMed ID: 33209632
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of
Clement MS; Gammelgaard KR; Nielsen AL; Sorensen BS
Transl Lung Cancer Res; 2020 Oct; 9(5):1904-1914. PubMed ID: 33209611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
